Bosutinib was recently approved for the treatment of chronic phase (CP), accelerated phase (AP), or blast phase (BP) Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to prior therapy. The approval was based on findings in a combined phase 1/2 single-arm trial.1 The recently reported phase 3 BELA trial compared bosutinib and imatinib as first-line treatments in patients with CP CML and reported no difference in complete cytogenetic response (CCyR) rates at 1 year, but improved major molecular response (MMR) rate and time to response, as well as a distinct safety profile.2
*Click on the links to the left for PDFs of the full article and related Commentary.